Title of article :
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Author/Authors :
Daniel J. Drucker، نويسنده , , John B Buse، نويسنده , , Kristin Taylor، نويسنده , , David A. Kendall، نويسنده , , Michael Trautmann، نويسنده , , Dongliang Zhuang، نويسنده , , Lisa Porter، نويسنده ,
Abstract :
Summary
Background
Exenatide is an incretin mimetic that shares glucoregulatory properties with glucagon-like peptide 1 (GLP-1), and improves glycaemic control, with progressive bodyweight reductions, when administered twice a day in patients with type 2
